Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03951389 · ClinicalTrials.gov registry record
INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer
A clinical trial, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- 750
- Enrollment target
NCT03951389 is a clinical trial that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 750 participants.
The verdict
NCT03951389 has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- 750 participants
- Enrollment target
Study Summary
This proposal seeks to further understand the contribution of the PIK3CA mutations in colon cancer, by correlating the type of hotspot mutation with the development of metastases in stage II and stage Ill patients. In order to do this, DNA will be extracted from either frozen or paraffin embedded colon cancer tissues to sequence PIK3CA, KRAS and BRAF. Clinical outcome data will be gathered to include metastases and survival to correlate with PIK3CA, KRAS and BRAF mutational status. Patients with stage II and stage Ill colon cancers will be identified in the University of New Mexico Human Tissue Repository and the NIH PLCO prevention trial biorepository. Existing banked tissues of stage II and Ill colon cancers will be collected. There will be no direct contact with living individuals. Epidemiological factors such as age, race, gender and outcome data of metastases and survival will be collected.
Interventions
- OTHER Non-interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2012-05-22 |
| Est. Completion | 2019-10-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03951389
The ClinicalTrials.gov registry entry for NCT03951389 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 750 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-interventional is the first listed.
NCT03951389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03951389 about?
NCT03951389 is a clinical study titled "INST 1204: PIK3CA Mutations as Biomarkers for Metastasis in Colon Cancer". This proposal seeks to further understand the contribution of the PIK3CA mutations in colon cancer, by correlating the type of hotspot mutation with the development of metastases in stage II and stage Ill patients. In order to do this, DNA will be extracted from either frozen or paraffin embedded c...
What is the current status of trial NCT03951389?
This trial is currently completed. The enrollment target is 750 participants. The study started on 2012-05-22. Estimated completion is 2019-10-21.
What interventions are being tested in trial NCT03951389?
The interventions under investigation include: Non-interventional (OTHER).
Who is sponsoring clinical trial NCT03951389?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.